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sub-cloning. This arose due to a mistake in transcribing informa-
tion from a larger table of MMP/TIMP oligonucleotide primer
sequences when the British Journal of Cancer paper was being put
together. However, this does not compromise the data reported in
the paper, which were obtained using the correct MMP-2
primer sequences forward = 5¢-GGCCCTGTCACTCCTGAGAT,
reverse = 5¢-GGCATCCAGGTTATCGGGGA, which as described
amplify a 474 bp PCR product. The methods that we have used for
MMP and TIMP quantification by RT-PCR are described in detail
in Wong et al (in press).
We are grateful to Jung et al for pointing out this error, and the
correct size of the MT1-MMP PCR product as 530 bp. There is
certainly a need for vigilance in the use of PCR as a research tool,
which we maintain in our own laboratories by subcloning and
sequence analysis of RT-PCR products to confirm their identities.
We agree that it is useful to identify the target gene sequences
used and the positions of primer pair combinations within those
sequences as a method of facilitating studies by other labs.
Consequently we have drawn up this information for the MMP-2,
MMP-9 and MT1-MMP targets used in our paper (Table 1).
However, we caution that even with such information in hand, it is
still necessary for other laboratories to confirm independently the
identities of the PCR products that they obtain, using appropriate
molecular criteria.
DR Edwards
School of Biological Sciences, University of East Anglia,
Norwich, Norfolk NR4 7TJ, UK
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Table 1 RT-PCR primer description
Target gene Primer sequence Target Position Product PCR
accession size cycle
number (bp) no.
Gelatinase-A GGCCCTGTCACTCCTGAGAT J03210 1337–1356 474 29
(MMP-2) GGCATCCAGGTTATCGGGGA 1810–1791
Gelatinase-B TGGACGATGCCTGCAACGTG NM 004994.1 1554–1573 455 33
(MMP-9) GTCGTGCGTGTCCAAAGGCA 2008–1989
MT1-MMP GCCCATTGGCCAGTTCTGGCGGG NM 004995.1 1178–1200 530 30
(MMP-14) CCTCGTCCACCTCAATGATGATC 1707–1685
GAPDH CGGAGTCAACGGATTTGGTCGTAT M33197 78–101 307 23
AGCCTTCTCCATGGTGGTGAAGAC 384–361
Sir,
We have read with great interest the article of Guerry and co-
workers ‘Prognostic value of histological and biological markers
in pharyngeal squamous cell carcinoma: a case-control study’
(Guerry et al, 1998). The authors present a comparison between
some histological features (grading, keratinization and vascular
emboli) and immunohistochemical features (expression of p53, c-
erb-B2, Rb and bcl-2) of primary tumour biopsies in two groups of
patients affected by pharyngeal cancer: patients who developed
distant metastasis (DM) and patients who did not. In the case-
control design each patient who developed a DM was matched to a
control patient with the same tumour site, the same nodal size and
level in the neck, and with an equal follow-up but free of DM. Out
of 65 patients there were 45 with positive neck nodes. It was found
that the risk for DM was halved in patients with tumours
expressing c-erb-B2 compared with patients with tumours
negative for c-erb-B2.
This result is of particular interest because it gives new perspec-
tive in the treatment planning and prognosis for these patients.
However, the design of this case-control study is not completely
correct.
Indeed, the two groups of patients with and without DM are
only clinically homogeneous. No data regarding the immunohisto-
chemical homogeneity of the neck nodes was presented. This is
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essential for two reasons. Firstly, patients with positive neck nodes
have a higher risk of developing DM as have those with negative
neck nodes (Leemans et al, 1993; Mamelle et al, 1994). Secondly, a
heterogeneity between the tumour cell populations of the primary
tumour site and the neck nodes is possible. Therefore an analysis of
the distribution of markers in the cervical nodes is essential.
Consequently, the results are questionable at this point in time.
A case-control study in which only patients with negative neck
nodes are selected will define which immunohistochemical
markers are related to DM.
F Carinci1 and PF Carls2
1Assistant Professor Maxillofacial Surgery, Ferrara University,
Italy; 2Consultant Oral & Maxillofacial Surgeon, John Radcliffe
Hospital, Oxford OX3 9DU, UK
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Sir,
As explained in our paper, the aim of our work was to study if
histological or biological factors, determined on initial biopsy
before treatment, could provide new prognostic information. It is a
clinical question, because it can help the clinician to choose the
initial treatment of the patient. For example, in the group of
patients with a higher risk to develop distant metastases, the clini-
cian could choose to begin with a general treatment (neo-adjuvant
chemotherapy for example) before the loco-regional treatment.
For that reason we focused on histo-biological factors which can
be determined before treatment.
The idea of studying immunohistochemical markers on neck
nodes is interesting, but it is a different question: it can only be
determined after surgery.
Nevertheless, the suggestion of Drs Carinci and Carls is impor-
tant. We are currently performing new studies so as to better
understand our results. We have seen that the expression of
c-erb-B2 can be present in non-transformed mucosa and disappear
in adjacent transformed mucosa (discussion of our paper). It will
be interesting to see if, when expressed in tumour, it can also
disappear in involved lymph nodes.
Thank you for your interest in our work.
M Guerry, L Vabre, M Talbot, G Mamelle, AM Leridant, C Hill,
J Bosq, B Luboinski and F Janot
Department de Chirugie Cervico-faciale, Institut Gustave Roussy,
39 Rue Camille, Desmoulins 94805,
France
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